Best Peptides for Libido & Sexual Health

Sexual desire and function are regulated by a complex interplay of neurological signaling, hormonal balance, and vascular health. Peptides that influence libido work through fundamentally different pathways. Some act centrally on melanocortin receptors in the brain to directly modulate desire. Others target upstream hormonal regulators like GnRH and growth hormone to restore the endocrine environment that supports healthy sexual function. A third category improves the vascular and tissue health that underpins physical arousal and performance.

The compounds below are ranked by the strength of published evidence for sexual health benefits, the directness of their mechanism of action on libido, and regulatory status. Each entry links to the full compound profile on PeptideHelp for detailed mechanism, protocol, and safety information.

1. PT-141 (Bremelanotide) — FDA-Approved for Sexual Desire

PT-141, marketed as Vyleesi, is the only FDA-approved peptide specifically indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women. Approved in 2019, it represents a fundamentally different approach to sexual dysfunction compared to vascular agents like PDE5 inhibitors. PT-141 is a melanocortin receptor agonist that acts on MC3R and MC4R receptors in the central nervous system, directly stimulating the neural circuits responsible for sexual desire and arousal. This central mechanism means it addresses the wanting component of sexual function — not just the mechanical capacity.

Clinical trials demonstrated that PT-141 significantly increased sexual desire scores and reduced distress related to low libido compared to placebo. The effect onset occurs approximately 45 minutes after subcutaneous injection, with a duration of action spanning several hours. Notably, PT-141 has also shown efficacy in men with erectile dysfunction in Phase II studies, particularly in cases where PDE5 inhibitors were ineffective — suggesting a neurological rather than vascular etiology.

The approved dose is 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Common side effects include nausea (affecting approximately 40% of users), flushing, and headache. Use is limited to no more than one dose per 24 hours and no more than 8 doses per month. PT-141 may transiently increase blood pressure and is contraindicated in uncontrolled hypertension.

2. Melanotan II — Melanocortin Agonist With Libido-Enhancing Effects

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone that acts as a non-selective agonist at multiple melanocortin receptor subtypes, including MC1R (skin pigmentation), MC3R, and MC4R (sexual arousal). While primarily known for inducing skin tanning without UV exposure, increased libido is one of the most consistently reported secondary effects. It was, in fact, the observation of pro-sexual effects during Melanotan II research that led to the development of PT-141 as a more selective compound specifically targeting sexual function.

The libido-enhancing effects of Melanotan II are mediated through MC4R activation in the hypothalamus and limbic system, the same pathway that PT-141 targets. However, because Melanotan II is non-selective, it simultaneously activates melanocortin receptors throughout the body, producing tanning, appetite suppression, and other systemic effects. This lack of selectivity is both its appeal for those seeking multiple effects and its primary drawback from a safety perspective.

Melanotan II is not FDA-approved and carries meaningful risks. Common side effects include nausea, facial flushing, and fatigue. More concerning are reports of changes to existing moles and nevi, including darkening and growth, which necessitate dermatological monitoring. There are case reports linking Melanotan II to atypical mole changes that required biopsy. Research doses typically range from 0.25mg to 0.5mg subcutaneously. This compound should only be considered with full awareness of its unapproved status and risk profile.

3. Kisspeptin-10 — Upstream Hormonal Regulator of Reproductive Function

Kisspeptin-10 is a truncated form of the kisspeptin neuropeptide that plays a critical role as the upstream gatekeeper of the hypothalamic-pituitary-gonadal (HPG) axis. By binding to the KISS1R receptor on GnRH neurons in the hypothalamus, kisspeptin-10 stimulates the release of gonadotropin-releasing hormone, which in turn triggers luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary. This cascade is the primary driver of testosterone production in men and estrogen/progesterone cycling in women.

Research published in the Journal of Clinical Investigation has shown that kisspeptin administration increases LH pulsatility and testosterone levels in healthy men. Neuroimaging studies have also demonstrated that kisspeptin enhances brain activity in regions associated with sexual arousal and attraction when subjects view romantic or erotic stimuli. This dual action — both hormonal and central — makes kisspeptin a uniquely interesting compound for sexual health research.

Kisspeptin-10 may be particularly relevant for individuals with hypothalamic dysfunction or suppressed HPG axis signaling, such as those recovering from exogenous hormone use. Research protocols use intravenous or subcutaneous administration at doses ranging from 1 to 10mcg/kg. Kisspeptin-10 is investigational and not FDA-approved. Its short half-life (approximately 28 minutes) limits practical application, though longer-acting analogs are under development.

4. BPC-157 — Vascular and Tissue Health for Indirect Sexual Benefits

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. While not a direct libido-enhancing peptide, BPC-157 supports sexual health through its well-documented effects on the nitric oxide system, vascular function, and tissue repair. Nitric oxide is the primary mediator of penile erection and plays a role in genital blood flow and arousal in both sexes. BPC-157 has been shown in animal studies to modulate the NO system and promote angiogenesis — the formation of new blood vessels.

The vascular benefits of BPC-157 may be particularly relevant for individuals whose sexual dysfunction has a circulatory component. By improving endothelial function and supporting the integrity of blood vessel walls, BPC-157 could enhance the vascular response that underlies physical arousal. Additionally, its potent tissue-healing properties may benefit individuals recovering from pelvic injuries, surgeries, or inflammatory conditions that impair sexual function.

Research protocols typically use 200–500mcg daily via subcutaneous injection, though oral administration has also been studied. BPC-157 has a favorable safety profile in animal research with no significant toxicity reported. It is investigational and not FDA-approved. The sexual health benefits of BPC-157 are indirect and inferred from its vascular and tissue-repair mechanisms rather than direct clinical trials measuring libido outcomes.

5. CJC-1295 + Ipamorelin — Growth Hormone Support for Hormonal Balance

CJC-1295 (a growth hormone-releasing hormone analog) and Ipamorelin (a selective growth hormone secretagogue) are frequently combined to elevate growth hormone levels through complementary mechanisms. CJC-1295 extends the duration of GH release by mimicking GHRH, while Ipamorelin triggers acute GH pulses via the ghrelin receptor without significantly raising cortisol or prolactin. Together, they produce a sustained and physiologically patterned elevation in growth hormone and IGF-1.

The connection to sexual health is indirect but meaningful. Growth hormone influences body composition, energy levels, sleep quality, and overall hormonal milieu — all of which are foundational to healthy sexual function. GH decline with age correlates with reductions in libido, erectile function, and sexual satisfaction. By restoring more youthful GH levels, this combination may improve the underlying physiological substrate that supports sexual desire and performance. Improved sleep quality from normalized GH pulsatility also supports testosterone production, which peaks during deep sleep.

Typical research protocols use CJC-1295 (no DAC) at 100–300mcg and Ipamorelin at 100–300mcg, administered together subcutaneously 1–3 times daily, often before bed and on an empty stomach. Both peptides are investigational and not FDA-approved. Side effects are generally mild and may include water retention, tingling, and transient hunger. The sexual health benefits are secondary to overall hormonal and metabolic optimization rather than a direct pro-sexual mechanism.

Libido Peptides Comparison Table

How to Choose the Right Peptide for Sexual Health

The first consideration is whether the issue is primarily one of desire, hormonal deficiency, or vascular function — each points to a different compound. For low sexual desire without a clear hormonal cause, PT-141 is the strongest evidence-based option and the only FDA-approved choice. It directly activates the brain pathways responsible for wanting, making it effective regardless of whether the underlying issue is psychological, stress-related, or idiopathic. If you are a premenopausal woman diagnosed with HSDD, Vyleesi is an approved treatment option worth discussing with your provider.

For individuals with suspected low testosterone or suppressed HPG axis function, Kisspeptin-10 offers an interesting upstream approach, though its short half-life limits practical use and it remains investigational. If vascular health is a contributing factor, BPC-157 may provide supportive benefits through improved blood flow and tissue repair. CJC-1295 and Ipamorelin are best suited for individuals seeking broad hormonal optimization where improved sexual function would be one benefit among many. Melanotan II should be approached with caution due to its non-selective action and risk of mole changes. In all cases, a thorough medical evaluation to identify the root cause of sexual dysfunction should precede any peptide protocol.

Frequently Asked Questions